Q-omics provides the consensus-scored ANKRD63 profile across patient tissues and cancer cell-line models. ANKRD63 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ANKRD63 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANKRD63 RNA expression shows 13,666 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, HNSC, and TGCT as cancer lineages where ANKRD63 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD63 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD63 survival associations across molecular data types. ANKRD63 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD63 RNA expression–survival associations across cancer types. High ANKRD63 expression shows unfavorable associations in KICH, UVM, ACC, BRCA and UCEC, but favorable associations in THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for ANKRD63 RNA expression.
This table summarizes ANKRD63 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD63. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD63 shows lower tumor expression in UCEC, KICH, STAD, KIRP and THCA and higher tumor expression in HNSC. The HNSC box plot shows higher ANKRD63 RNA expression in tumor versus normal tissue (log2 FC = +0.232, t-test p = .003).
This table shows molecular features associated with ANKRD63 in patient tissues and cancer cell lines. In patient samples, ANKRD63 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD63 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
